Applied Therapeutics: Update Following Failure In Diabetic Cardiomyopathy (Downgrade)

[ad_1]

Rare diseases written on wooden blocks together with medical stethoscope, Health concept

Andrzej Rostek

Thesis overview

In my prior coverage I recommended APLT as a “Buy” on the prospects of positive interactions with the FDA and NDA submission of AT-007 for the treatment of galactosemia. On that front everything is going as planned so

Change from baseline in Peak VO2
Placebo AT-001 Difference (AT-001 minus placebo)
Subgroup on SGLT-2/GLP-1* 0.17875 -0.20125 -0.38
Subgroup not receiving SGLT-2/GLP-1 -0.54 0.08 0.62
Total -0.31 -0.01 0.3**

[ad_2]
Source link

Leave a Reply

Your email address will not be published. Required fields are marked *